Fig 1: PAI-1 promoted Src inhibitor resistance, cell proliferation and migration in breast cells. A, Relative cell viability was determined in SKBR-3 and SKBR-3/SI cells following treatment with 10 ng/mL rPAI-1 and PAI-039 for 72 h by CCK8 assay. IC50 values of SKBR-3 and SKBR-3/SI cells were presented in the mini-tables. B, OD value in SKBR-3 and SKBR-3/SI after treatment of 1, 10 or 100 µmol/L rPAI-1 and PAI-039, respectively, for 24, 48 and 72 h. C, Colony formation showed the proliferation of SKRB-3 and SKBR-3/SI after treatment of 10 ng/mL rPAI-1 and PAI-039, respectively. D, Cell apoptosis of SKBR-3 and SKBR-3/SI after exposure to 10 ng/mL rPAI-1 or PAI-039 for 48 h was shown. E, Cell migration analysis in SKBR-3 and SKBR-3/SI cells treated with 10 ng/mL rPAI-1 and PAI-039 were performed. The error bars represent the mean of 3 separate determinations ± SD. *P < .05, **P < .01, ***P < .001
Fig 2: PAI-1 upregulated the expression of CCL5 in SKBR-3/SI cells. A, qRT-PCR verified the increased expression of CCL5 in SKBR-3/SI cells. B,C, The expression level of CCL5 and the secretion level of CCL5 were detected in SKBR-3 after treated with 10 ng/mL of rPAI-1and PAI-039 for 48 h by qRT-PCR and ELISA, respectively. D, qRT-PCR analysis of PAI-1 mRNA expression post-siRNA knockdown of PAI-1 in SKBR-3/SI cells. E, PAI-1 and CCL5 expression were determined in SKBR-3/SI after knockdown of PAI-1 by western blot. The error bars represent the mean of 3 separate determinations ± SD. *P < .05, **P < .01, ***P < .001
Fig 3: Upregulation of PAI-1 in saracatinib-resistant cells. A, Gene ontology analysis of gene differentially expressed in SKBR-3 and SKBR-3/SI was performed. B, Relative mRNA expression of PAI-1 in SKBR-3 and SKBR-3/SI cells. C, PAI-1 expression in SKBR-3 and SKBR-3/SI cells was detected by western blot. The error bars represent the mean of 3 separate determinations ± SD. ***P < .001
Fig 4: PAI-1 and CCL5 expression was higher in SKBR-3/SI tumors compared to SKBR-3 tumors in vivo. A,B, The gross morphology of tumors and the final xenograft tumor weights measured on day 42 after injection of tumor cells (n = 6, **P < .01). C, The final xenograft tumor stained with routine H&E staining (200×, 400×). D, Representative images of expression of PAI-1, CCL5 and Ki-67 in 2 groups of tumor xenografts identified by immunohistochemistry. **P < .01
Supplier Page from Abcam for Anti-PAI1 antibody [EPR17795]